null

null

null

null

null

null

null

null

null

null

null

null

null

Minimal disclosed debt; small clinical-stage research institute with limited external financing, low leverage ratio estimated <0.5x

Near-zero sensitivity; negligible interest-bearing debt, rate changes have immaterial impact on financing costs

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

Houston, TX single-site operations; antineoplaston synthesis depends on specialized chemical precursors with limited alternative suppliers

Virtually no international revenue; primary exposure is domestic US clinical trial patients, negligible sovereign currency devaluation risk

Single-country operation (USA); no material international revenue markets, currency devaluation exposure effectively null

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

Antineoplaston compound synthesis is proprietary and internally controlled; no single external vendor exceeds 30% of input cost publicly identified

Not cloud-dependent; clinical research institute operates on-site labs and clinical facilities, cloud termination would be minimally disruptive

Research and clinical services model; secondary administrative functions may use cloud but no material operational dependency

Minimal API coupling risk; not a software business, no material third-party API integrations in core antineoplaston therapy delivery

Low Howey risk; revenue from patient treatment fees and clinical grants, not investment contracts or profit-sharing arrangements

Very High

HIPAA primary compliance obligation; GDPR exposure minimal given US-only patient base, CCPA applies to limited California patient data

Negligible antitrust risk; niche experimental oncology provider with no market-dominant position or pricing power in broader oncology market

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Predominantly transactional; patient treatment fees and clinical trial grants, minimal recurring contracted revenue, estimated <10% recurring

Direct patient treatment fees for antineoplaston therapy at Houston clinic; supplemented by research grants and donations

Cost-plus treatment pricing; FDA-restricted commercial sale limits pricing power, compassionate use and clinical trial constraints cap revenue upside

Very low; FDA oversight, experimental status, and compassionate use framework severely constrain ability to raise treatment prices

Estimated gross margin 20–40%; high direct costs of proprietary compound synthesis and clinical staff offset by premium treatment fees

No free-rider leakage; treatment is direct-pay or grant-funded with no public-access or freemium component

Headcount-linear growth; clinical operations require proportional physician, nursing, and lab staff increases with patient volume

High marginal cost; each additional patient requires direct clinical labor and compound synthesis, no scalable digital leverage

Not applicable; no franchise network, single-location owner-operated clinical research institute

At 10x scale, CAC would rise sharply; patient acquisition via referral and media is non-scalable without FDA approval expansion

No network effects; therapy efficacy and patient volume are independent, no platform or data-sharing flywheel present

-163660.8% Return on Assets (Negative equity)

Moderate resilience; cancer patients prioritize treatment regardless of economic cycle, but out-of-pocket payment model creates affordability risk

Terminal and treatment-resistant cancer patients seeking experimental antineoplaston therapy, primarily self-pay or compassionate use

Families of pediatric brain tumor patients; historically a significant referral and advocacy segment for Burzynski treatments

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

Capital maintained in existing Houston facility; no evident reallocation to new infrastructure, legacy operational maintenance mode

0000724445

BZYR